Mark Crowley
Internal Medicine · Peru, INNPI 1568442481
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,580 and has fallen 85.4% since, to $230 in 2025. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$532
- Astellas Pharma US Inc$524
- AstraZeneca$433
- AbbVie$363
- Kowa Pharmaceuticals America, Inc.$356
- Amarin Pharma, Inc.$347
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,66896%
- Education$1714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $532 |
| Astellas Pharma US Inc | 25 | $524 |
| AstraZeneca | 28 | $433 |
| AbbVie | 33 | $363 |
| Kowa Pharmaceuticals America, Inc. | 31 | $356 |
| Amarin Pharma, Inc. | 20 | $347 |
| Pfizer | 18 | $311 |
| GSK | 8 | $119 |
| Amgen | 5 | $88 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 6 | $76 |
| Novartis | 4 | $65 |
| Corcept Therapeutics | 3 | $58 |
| Boehringer Ingelheim | 4 | $57 |
| Bayer | 3 | $56 |
| Exact Sciences | 2 | $46 |
| Gilead | 2 | $39 |
| Lilly USA, LLC | 2 | $28 |
| Eisai Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Vanda Pharmaceuticals Inc. | 2 | $23 |
| Abbott | 1 | $19 |
| Merck | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Covis Pharma GmbH | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,838 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 13 | $298 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $180 |
| Omeprazole | 12 | $116 |
| Gabapentin | 12 | $94 |
| Meloxicam | 15 | $65 |
| Amlodipine Besylate | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Peru
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
- David IloFort Wayne$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.